Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Recombination00:57

Viral Recombination

25.1K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
25.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.9K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K
Viral Structure00:56

Viral Structure

74.5K
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
74.5K
Viral Mutations00:36

Viral Mutations

39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Infection01:20

Infection

12.6K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
12.6K
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

786
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
786

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inoculum effect of high concentrations of methicillin-susceptible Staphylococcus aureus on the efficacy of cefazolin and other beta-lactams.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2017
Same author

High prevalence of mcr-1, mcr-3 and mcr-5 in Escherichia coli derived from diseased pigs in Japan.

International journal of antimicrobial agents·2017
Same author

Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15).

Haematologica·2017
Same author

Microsecond resolved single-molecule FRET time series measurements based on the line confocal optical system combined with hybrid photodetectors.

Physical chemistry chemical physics : PCCP·2017
Same author

Left atrial ejection force predicts the outcome after catheter ablation for paroxysmal atrial fibrillation.

Journal of cardiovascular electrophysiology·2017
Same author

Advantages of Staged Angioplasty in a Patient with Internal Carotid Artery Pseudo-Occlusion Besides Prevention of Cerebral Hyperperfusion Syndrome.

World neurosurgery·2017

Related Experiment Video

Updated: Feb 4, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.8K

[Immunotherapy using T cells for treating viral infections].

Satoshi Takahashi1

  • 1Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|October 12, 2018
PubMed
Summary

Hematopoietic stem cell transplant recipients face high viral infection risks. Virus-specific T-cell therapy shows promise but faces time constraints, with recent advances improving clinical applicability.

Keywords:
Allogeneic hematopoietic stem cell transplantationImmunotherapyThird-party donor bankVirus-specific T cells

More Related Videos

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.6K
Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis
09:35

Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis

Published on: August 9, 2013

12.3K

Related Experiment Videos

Last Updated: Feb 4, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.8K
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.6K
Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis
09:35

Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis

Published on: August 9, 2013

12.3K

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Virology

Background:

  • Hematopoietic stem cell transplantation (HSCT) recipients often experience severe immunosuppression and immune dysregulation.
  • Graft-versus-host disease (GVHD) and other causes increase susceptibility to viral infections, including cytomegalovirus and Epstein-Barr virus reactivation.
  • These viral infections are a major cause of morbidity and mortality in transplant patients.

Purpose of the Study:

  • To review the development and clinical application of virus-specific T-cell therapy for HSCT recipients.
  • To highlight the challenges and recent advancements in generating and utilizing these therapies.

Main Methods:

  • Generation of virus-specific T cells using immunogenic epitope peptides or Epstein-Barr virus-leukocyte-transformed cell lines (EBV-LCL) from donors.
  • Exploration of advanced techniques like direct donor T-cell selection using peptide-HLA multimers or cytokine capture.
  • Development of virus-specific T-cell banks using third-party donors.

Main Results:

  • Traditional methods for generating virus-specific T cells take 8-10 weeks, limiting immediate clinical use.
  • Recent advances have significantly reduced production times and broadened therapeutic applicability.
  • Virus-specific T-cell therapy is emerging as a viable immunotherapy for viral infections post-transplantation.

Conclusions:

  • Virus-specific T-cell therapy is a critical advancement in managing life-threatening viral infections in immunocompromised patients.
  • Ongoing research and technological improvements are making this therapy more accessible and effective.
  • This approach serves as a prototype for future T-cell immunotherapies against infections and malignancies.